The failure of a key late-stage oncology trial with Gilead, based on an external data monitoring committee's recommendation, exposes potential weaknesses in R&D data analysis.
Filing excerpt
The Company, in collaboration with Gilead Sciences, Inc., is discontinuing the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Trodelvy in combination with Keytruda compared to Keytruda monotherapy in certain patients with previously untreated metastatic NSCLC whose tumors expressed PD-L1 (tumor proportion score ≥50%).
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
Competitors
Competitors named
sec-10qdataInvestmentGet every 10-Q signal for Merck and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/fbf1e111-5ae8-4a99-ab25-ac9b6ee34e8b returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.
{
"signal_id": "fbf1e111-5ae8-4a99-ab25-ac9b6ee34e8b",
"signal_type": "sec-10q",
"signal_subtype": "dataInvestment",
"detected_at": "2026-08-11T08:10:26.837+00:00",
"company": {
"name": "Merck",
"domain": "merck.com"
},
"data": {
"detail": "The failure of a key late-stage oncology trial with Gilead, based on an external data monitoring committee's recommendation, exposes potential weaknesses in R&D data analysis. This setback creates a compelling event for data analytics and AI vendors to offer solutions that improve clinical trial modeling and success rates.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "Merck & Gilead discontinue Phase 3 trial, highlighting clinical data analysis challenges",
"excerpts": "The Company, in collaboration with Gilead Sciences, Inc., is discontinuing the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Trodelvy in combination with Keytruda compared to Keytruda monotherapy in certain patients with previously untreated metastatic NSCLC whose tumors expressed PD-L1 (tumor proportion score ≥50%).",
"relevance": 0.7,
"sentiment": "negative",
"confidence": "medium",
"source_url": "https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm",
"filing_date": "2026-08-07",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Target for data vendors",
"signal_category": "technology",
"vendors_mentioned": [
"WuXi Vaccines"
],
"competitors_mentioned": [
"Gilead Sciences, Inc.",
"Eisai Co., Ltd.",
"AstraZeneca",
"Bayer AG",
"Daiichi Sankyo",
"Moderna Inc.",
"Bristol Myers Squibb Company",
"Jiangsu Hengrui Pharmaceuticals Co. Ltd."
]
}
}
curl https://signals.autobound.ai/v1/signals/fbf1e111-5ae8-4a99-ab25-ac9b6ee34e8b \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"merck.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.